Skip to main content
. 2021 Oct 11;11:20175. doi: 10.1038/s41598-021-99726-7

Table 1.

Demographics and history.

Demographics and history Group 1 Group 2 Group 3 p
Age Median (range) 54 (23–92) 51.5 (28–82) 51 (24–84) 0.086
BMI
Underweight n (%) 5 (0.8) 1 (2.3) 3 (2.9) 0.476
Normal 155 (25.3) 10 (22.7) 23 (22.3)
Overweight 226 (36.9) 17 (38.6) 44 (42.7)
Obese 227 (37.0) 16 (36.4) 33 (32.0)
BMI Median (range) 28.3 27.8 27.8 0.737
(14.9–51.3) (18.3–44.3) (16.5–48.3)
Smoking
No n (%) 471 (65.1) 38 (76.0) 82 (66.1) 0.287
Yes 253 (34.9) 12 (24.0) 42 (33.9)
Hormone use
No n % 407 (52.9) 30 (60.0) 80 (63.5) 0.064
OC or HRT 164 (21.3) 15 (30.0) 24 (19.0)
OC 145 (18.9) 4 (8.0) 17 (13.5)
HRT 31 (4.0) 0 (0) 5 (4.0)
OC + HRT 22 (2.9) 1 (2.0) 0 (0)
Diabetes
No n % 684 (84.4) 51 (89.5) 116 (86.6) 0.509
Yes 126 (15.6) 6 (10.5) 18 (13.4)
Comorbid disease
No n % 221 (47.5) 15 (60.0) 30 (48.4) 0.477
Yes 244 (52.5) 10 (40.0) 32 (51.6)
Family history
No n % 607 (77.1) 45 (83.3) 98 (76.0) 0.531
Yes 180 (22.9) 9 (16.7) 31 (24.0)
Menopausal status
Premenopausal n % 329 (36.3) 27 (40.3) 72 (41.4) 0.161
Postmenopausal 573 (63.3) 40 (59.7) 99 (56.9)
Male 3 (0.4) 0 (0) 3 (1.7)
CEA Median (range) 1.7 2 2.2 < 0.001
(0.2–56.2) (0.4–26.1) (0.2–312.1)
CA15-3 Median (range) 15.1 18.2 20.1 < 0.001
(0.5–333.7) (4–127.1) (5.8–698.5)

BMI body mass index, OC oral contraceptives, HRT hormone replacement therapy.